Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Millipore launches new excipient Parteck SLC

Merck Millipore launches new excipient Parteck SLC

24th October 2013

Merck Millipore has announced the availability of Parteck SLC, a new silica-based excipient for use in the drug development process.

The product features a unique surface structure that delivers significantly increased loadability for active pharmaceutical ingredients (APIs), while also enhancing drug solubility and bioavailability.

Its unique pore structure enables loading of oral dosage forms with amorphously distributed API to the highest levels and its user-friendly particle size and bulk density allows for easy loading, tableting or capsule creation.

Feasibility studies carried out by Merck Millipore have demonstrated the superior performance on dissolution of Parteck SLC both in vitro and in vivo.

Dr Matthias Bucerius, head of pharmaceutical raw materials, said: "With the addition of Parteck SLC to our extensive portfolio of excipients, drug developers now have a new option to help increase solubility and bioavailability and advance drug development."

This comes after the company recently received Stevie Awards at the American Business Awards for two of its products, the Muse Cell Analyser and Direct Detect Protein Quantitation System.ADNFCR-8000103-ID-801653230-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.